U.S. and Europe In-vivo Pharmacology Market, By Service Type (Toxicology studies, PK and PD Studies, Maximum Tolerated Dose Studies, Biomarkers Testing and Bio analysis, Animal Disease Models, ADME studies, and Others), By Application (Oncology, Inflammation and Immunology, Cardiology, Neurology, Pain Management, Fibrosis, Metabolic Diseases, Respiratory Diseases, Infectious Diseases, and Others), By End User (Biotechnology and Pharmaceutical Companies, Contract Research Organizations (CROs), and Others)

The U.S. and Europe in-vivo pharmacology market is estimated to be valued at USD 21,793.6 Mn in 2026 and is expected to reach USD 35,688.4 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 7.3% from 2026 to 2033. The U.S. and Europe in-vivo pharmacology market comprises the use of living animal models to evaluate safety, efficacy, pharmacokinetic, and pharmacodynamic parameters of potential drugs. It functions as a bridge between in-vitro screening, early-stage drug discovery and human trials for further validation and safety. The U.S. and Europe in-vivo pharmacology market is driven by substantial R&D investment from biopharmaceutical organizations in these regions, significant regulatory support systems, presence of academic research institutions and a highly competitive environment within the market. Furthermore, increasing prevalence of diseases, such as cancer and neurological disorders, which often pose complexity during development phase, further accentuates the role of the in-vivo pharmacology segment in the U.S. and Europe in-vivo pharmacology market. Market Dynamics The U.S. and Europe in-vivo pharmacology market is fueled by the growing R&D spending by pharma and biopharma companies, rising incidences of chronic and rare diseases and increasing demand for the validation of novel drugs via in-vivo assessment. Regulatory requirements from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for comprehensive in-vivo studies before clinical trials, coupled with the expanding pipelines of biologics, cell therapies, and gene therapies, continue to strengthen the demand for advanced in-vivo pharmacology services. However, a number of constraints are present in the market, such as rising ethical concerns and public attention about the animal testing, high cost for animal models, development of sophisticated animal research infrastructure, and specialized animal models. Nevertheless, expanding outsourcing to contract research organizations (CROs) and technological advancements such as humanized animal models, patient-derived xenografts, and non-invasive in-vivo imaging are creating significant opportunities by improving translational accuracy, operational efficiency, and the overall value of preclinical pharmacology studies. Key Features of the Study • This report provides in-depth analysis of the U.S. and Europe in-vivo pharmacology market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the U.S. and Europe in-vivo pharmacology market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Charles River Laboratories, Labcorp Drug Development, Pharmaron, ICON plc, Parexel International, Eurofins Scientific, Evotec, Inotiv, Taconic Biosciences, and Altasciences • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The U.S. and Europe in-vivo pharmacology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. and Europe in-vivo pharmacology market Market Segmentation • Service Type Insights (Revenue, USD Mn, 2021 - 2033) o Toxicology studies o PK and PD Studies o Maximum Tolerated Dose Studies o Biomarkers Testing and Bio analysis o Animal Disease Models o ADME studies o Others • Application Insights (Revenue, USD Mn, 2021 - 2033) o Oncology o Inflammation and Immunology o Cardiology o Neurology o Pain Management o Fibrosis o Metabolic Diseases o Respiratory Diseases o Infectious Diseases o Others • End User Insights (Revenue, USD Mn, 2021 - 2033) o Biotechnology and Pharmaceutical Companies o Contract Research Organizations (CROs) o Others • Key Players Insights o Charles River Laboratories o Labcorp Drug Development o Pharmaron o ICON plc o Parexel International o Eurofins Scientific o Evotec o Inotiv o Taconic Biosciences o Altasciences